Medworxx Aligns With National Institute for Health and Clinical Excellence Guidance

TORONTO, June 13, 2011 -

    - Medworxx UMS Patient Flow Solution is
Optimized to Support NICE Guidance and Pathways

Medworxx Inc. (TSXV: MWX), an emerging leader in clinical
patient flow solutions, announces the alignment of its health
information technology solution to guidance set by the National
Institute for Health and Clinical Excellence (NICE) in the United
Kingdom.  For more than 300 international hospitals, Medworxx
ensures the daily use of guidance-based patient flow
assessments.

“Like the NHS and NICE, we rely on an evidence-base for the
clinical cornerstones of our system - and this depth in clinical
best practices makes our solutions easily adaptable to
international guidance. We are proud that our patient flow solution
is in line with the guidance most depended upon in the UK,” says
Wendy McLaughlin, RN, Vice President, Clinical Services for
Medworxx.

Clinical alignment with guidance and pathways is
mission-critical to the company’s internationally-offered solution
which assesses barriers and delays in daily patient flow against
clinical criteria.

“In hospitals in England and Wales, such as Royal Liverpool and
Broadgreen University Hospitals, compliance with NICE guidance is
essential to avoid clinically unnecessary admissions to hospital,
to reduce length of stay in-hospital, and to transition to
home-based programmes. Applying the Medworxx criteria in accordance
with NICE, alongside our other patient journey and commissioning
tools, enables us to assess appropriate levels of care and
patients’ readiness for discharge - and ultimately to inform Trusts
and Commissioners of the major opportunities and solid actions they
can take in this direction,” said Karen Dunwell, Chief Executive,
ModelAdvice DC Consulting Ltd UK. “This will lead to the
development of a vertically integrated health system with the
clinical quality and affordability required by our NHS
environment.”

NICE is engaged in developing and defining pathways, standards
of healthcare and a quality and outcomes framework for the United
Kingdom, in addition to making recommendations to the National
Health Service (NHS) on new and existing medicines, treatments and
procedures. Medworxx incorporates review of NICE guidelines along
with other international sources into building the evidence-based
clinical criteria at the heart of its patient flow solutions.

About Medworxx

The Medworxx Community of Care engages more than 500,000 people
at over 300 hospitals across Canada, Unites States and United
Kingdom to manage daily challenges in clinical patient flow, and
requirements in compliance and education. Founded in 2004, Medworxx
Inc. is based in Toronto, Ontario, Canada and serves international
markets. The company is publicly traded on the TSX Venture Exchange
(TSXV: MWX). For more information, visit href="www.medworxx.com">www.medworxx.com.

The statements made in this press release may contain
forward-looking statements that may involve a number of risks and
uncertainties. Actual events or results could differ materially
from the company’s expectations and projections. The TSX Venture
Exchange has not reviewed this press release and neither approved
nor disapproved the information contained in this press
release.

For further information:
Julia Zarb, PhD
SVP Marketing & Strategy,  Medworxx Inc.
Suite 700, 121 Richmond St West, Toronto, Canada M5H 2K1
T: +1-800-321-1591 | T: +1-416-642-1278 x322 | M:
+1-416-418-3641
Jzarb@medworxx.com
|  href="www.Medworxx.com">www.Medworxx.com

.